2Spacek J, Jilek P,et al.Antifungal immunity and its mechanism in female genitalia [J]. Ceska Gynekol, 2004,69(2):133 - 140.
3Taylor B N, Saavedra M, Fidel P L J. Local Th1/Th2 Cytokine production during experimental vaginal candidiasis potential Importance of transforming growth factor-beta [J].Med Mycol,2000,38(6):419 - 431.
4Wormley E L J, Chaiban J, Fidel P L J. Cell adhesion molecule and Lymphocyte activation marker expression during experimental Vaginal candidiasis [J]. Infecs Lmmun, 2001,69(8):5072 - 5079.
5Nawrot V, Grzybek H K, Zielska V, et al. The study of cell mediated immune response in recurrent Vulvovaginal candidiasis[J]. FEMs Lmmunol Med Microbiol,2000,29(2) :89- 94.
6Ghaleb M, Hamad M, Abu E K H. Vaginal T Lymphocye population kinetics during experimental vaginal: candidosis evidence for a possible role of CD8^+ T ceils in protection against vaginal candidosis [J]. Clin Exp Lmmunol, 2003, 131(1):26-33.
7Sobel J D. Recurrent Vulvovaginal candidasis (RVVC) [J].International Jour of STD&AIDS,2001,2:9.
8Sobel J D. Pathogenesis of RVVC[J]. Curr Infect Dis Rep,2002,4(6) :514- 519.
9Barousse M I.Vaginal yeast colonisation prevalence of vaginitis and associated local immunity in adolescents [J].Sexually Transmit ted Lmfection, 2004,80(1) :48 - 53.
10David A .Chronic vulvovaginal candidiasis[J]. New England Jour of Medicine,2004,351(24) :2554 - 2556.
4Owen MK,Clenney TL. Management of vaginitis[J], Am Faro Physician,2004,70(11) :2125-2132.
5Meyer H,Goettlicher S,Medling W. Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the con ventional antimycotic therapy[J]. Mycoses, 2006,49 : 202-209.
6乐杰.妇产科学[M].6版.北京:人民卫生出版社,2006:110.
7Vrablik J,Masata J,Jedlictmva A,et al. Prospective study of the prevalefloe of different candida strains and their senfitivity to different antimycotic treatment in women with vlIIvovaginal canidiasis[J].Coeska Gynekol, 2007,72(1) : 27.
